Apixaban Versus Low-Molecular-Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis
Journal of Clinical Medicine · 08.07.2026 · 15 (14) · 5341
DOI: 10.3390/jcm15145341 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 08.07.2026. Verfasst von Sumit Aggarwal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Indian Council of Medical Research, New Delhi 110029, India. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
Venous thromboembolism (VTE), particularly in the context of cancer-associated thrombosis (CAT), is a major cause of morbidity and mortality in patients with malignancy. While apixaban has emerged as a potential alternative to low-molecular-weight heparins (LMWHs), uncertainty remains regarding the consistency of its safety profile across different LMWH agents.
Methods
This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. A comprehensive literature search was performed across PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials.
Results
Six randomized controlled trials were included. Apixaban was associated with a reduced risk of recurrent VTE (RR 0.66, 95% CI 0.45–0.96). However, safety outcomes varied depending on the LMWH comparator. Compared with dalteparin, apixaban was associated with a higher risk of clinically relevant non-major bleeding (CRNMB) (log RR 0.38; 95% CI 0.02 to 0.75), whereas, compared with enoxaparin, it was associated with a lower risk (log RR −0.49; 95% CI −0.96 to −0.02).
Conclusions
These findings suggest potential differences in safety profiles across individual LMWH agents. However, given the limited number of included trials and clinical heterogeneity, the results should be interpreted cautiously. Further large-scale studies are required to confirm these observations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Indian Council of Medical Research, New Delhi 110029, India.
- All India Institute of Medical Sciences, New Delhi 110029, India.
ORCID-Profile: Sumit Aggarwal, Vikram Singh, Sachit Anand
Zitieren
APA
Aggarwal, S., Singh, V., Bhasin, A., Anand, S., & Tabassum, H. (2026). Apixaban Versus Low-Molecular-Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 15(14), 5341. https://doi.org/10.3390/jcm15145341
Vancouver
Aggarwal S, Singh V, Bhasin A, Anand S, Tabassum H. Apixaban Versus Low-Molecular-Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2026;15(14):5341. doi:10.3390/jcm15145341
BibTeX
@article{Aggarwal2026,
author = {Aggarwal, Sumit and Singh, Vikram and Bhasin, Aayushi and Anand, Sachit and Tabassum, Heena},
title = {Apixaban Versus Low-Molecular-Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {14},
pages = {5341},
doi = {10.3390/jcm15145341}
}
EUVIMED